Low bone density medications may have protective effect on endometrial cancer

March 21, 2012

Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study at Henry Ford Hospital.

Endometrial cancer affects more than 45,000 women a year in the U.S., usually in their 60s, although it can occur before 40. A type of uterine cancer, it's the most commonly diagnosed gynecologic cancer, and there is no known for women at high risk of developing it.

"The results of the study suggest that use of medications may have a protective effect on endometrial cancer, or that women who take them get a less-aggressive cancer," says Sharon Hensley Alford, Ph.D, lead author of the study, and a researcher in at Henry Ford Hospital.

The classification for these medications is bisphosphonates.

In the fifth year of the ongoing trial, all participants were asked to complete a supplemental questionnaire, which included questions about their use of medications that treat thinning bones.

A total of 29,254 women were included in the analysis, for which 115 endometrial cancers have been diagnosed since the completion of the questionnaires.

The rate of endometrial cancer among women who had taken was approximately half that of women who had never taken the medication (9.6 vs. 18.7 per 10,000 person years). The effect was more significant with less-aggressive cancers.

Dr. Alford is presenting the study March 24 at the Society of Gynecologic Oncology's 2012 Annual Meeting on Women's Cancer in Austin, Texas.

Henry Ford researchers used data from the National Cancer Institute's Prostate, Lung, Colorectal, and Ovarian Screening Trial, which collected data on all cancer outcomes for trial participants.

At the time the women were recruited for the trial, they ranged from 55 to 70 years old.

Women with missing information on bone medication use were excluded. Only women who had not had a hysterectomy were included in the analysis.

Women without a cancer diagnosis at the time of the questionnaire were separated into groups: those who reported current or past use of a bisphosphonate, defined as "ever used", and women who had never used such medications.

This study alone would not change clinical practice, and more study is necessary, according to Dr. Alford.

"This was a retrospective study, with self-reported data," says Dr. Alford. "A clinical trial, with closely monitored data, needs to be done for definitive results."

Explore further: Significant weight gain in adulthood increased risk for endometrial cancer

Related Stories

Significant weight gain in adulthood increased risk for endometrial cancer

October 24, 2011
Postmenopausal women who gained weight during adulthood had an increased risk for endometrial cancer compared with women who maintained a stable weight, according to data from the American Cancer Society's Cancer Prevention ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.